About this Journal Submit a Manuscript Table of Contents
Bone Marrow Research
Volume 2012 (2012), Article ID 916479, 5 pages
http://dx.doi.org/10.1155/2012/916479
Review Article

Curability of Multiple Myeloma

University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA

Received 22 November 2011; Accepted 23 February 2012

Academic Editor: Luciano J. Costa

Copyright © 2012 Raymond Alexanian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Alexanian, B. Barlogie, and S. Tucker, “VAD-based regimens as primary treatment for multiple myeloma,” American Journal of Hematology, vol. 33, no. 2, pp. 86–89, 1990. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Alexanian, M. A. Dimopoulos, K. Delasalle, and B. Barlogie, “Primary dexamethasone treatment of multiple myeloma,” Blood, vol. 80, no. 4, pp. 887–890, 1992. View at Scopus
  3. D. Weber, K. Rankin, M. Gavino, K. Delasalle, and R. Alexanian, “Thalidomide alone or with dexamethasone for previously untreated multiple myeloma,” Journal of Clinical Oncology, vol. 21, no. 1, pp. 16–19, 2003. View at Scopus
  4. M. Attal, J. L. Harousseau, T. Facon et al., “Single versus double autologous stem-cell transplantation for multiple myeloma,” New England Journal of Medicine, vol. 349, no. 26, pp. 2495–2502, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. J. J. Lahuerta, M. V. Mateos, J. Martínez-Lopez et al., “Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5775–5782, 2008. View at Publisher · View at Google Scholar
  6. J. L. Harousseau, H. Avet-Loiseau, M. Attal et al., “Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5720–5726, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Wang, S. Giralt, K. Delasalle, B. Handy, and R. Alexanian, “Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma,” Hematology, vol. 12, no. 3, pp. 235–239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Wang, K. Delasalle, S. Giralt, and R. Alexanian, “Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD),” Hematology, vol. 15, no. 2, pp. 70–73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Alexanian, D. Weber, S. Giralt et al., “Impact of complete remission with intensive therapy in patients with responsive multiple myeloma,” Bone Marrow Transplantation, vol. 27, no. 10, pp. 1037–1043, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Alexanian, D. Weber, K. Delasalle, B. Handy, R. Champlin, and S. Giralt, “Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma,” Bone Marrow Transplantation, vol. 34, no. 3, pp. 229–234, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Blade, D. Samson, D. Reece et al., “Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation,” British Journal of Haematology, vol. 102, no. 5, pp. 1115–1123, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Kaplan and P. Meier, “Nonparametric estimation from incomplete observations,” Journal of the American Statistical Association, vol. 53, no. 282, pp. 457–481, 1958.
  13. N. Mantel, “Evaluation of survival data and two new rank order statistics arising in its consideration,” Cancer Chemotherapy Reports, vol. 50, no. 3, pp. 163–170, 1966. View at Scopus
  14. J. R. Anderson, K. C. Cain, and R. D. Gelber, “Analysis of survival by tumor response,” Journal of Clinical Oncology, vol. 1, no. 11, pp. 710–719, 1983. View at Scopus
  15. M. Wang, K. Delasalle, L. Feng et al., “CR represents an early index of potential long survival in multiple myeloma,” Bone Marrow Transplantation, vol. 45, no. 3, pp. 498–504, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Desikan, B. Barlogie, J. Sawyer et al., “Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities,” Blood, vol. 95, no. 12, pp. 4008–4010, 2000. View at Scopus
  17. B. Barlogie, G. J. Tricot, F. Van Rhee et al., “Long-term outcome results of the first tandem autotransplant trial for multiple myeloma,” British Journal of Haematology, vol. 135, no. 2, pp. 158–164, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Barlogie, E. Anaissie, J. Haessler et al., “Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma,” Cancer, vol. 113, no. 2, pp. 355–359, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. F. S. San Miguel, J. Almeida, G. Mateo et al., “Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome,” Blood, vol. 99, no. 5, pp. 1853–1856, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Ladetto, G. Pagliano, S. Ferrero et al., “Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma,” Journal of Clinical Oncology, vol. 28, no. 12, pp. 2077–2084, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. D. van Lammeren-Venema, J. Regelink, I. Riphagen, S. Zweegman, H. Otto, and J. Zijlstra, “F-fluoro-deoxyglucose position emission tomography in assessment of myeloma-related bone disease,” Cancer, vol. 11, pp. 1–11, 2011.
  22. S. V. Rajkumar, “Treatment of myeloma: cure vs control,” Mayo Clinic Proceedings, vol. 83, no. 10, pp. 1142–1145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Fassas, J. Shaughnessy, and B. Barlogie, “Cure of myeloma: hype or reality?” Bone Marrow Transplantation, vol. 35, no. 3, pp. 215–224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Hari, M. C. Pasquini, and D. H. Vesole, “Cure of multiple myeloma—more hype, less reality,” Bone Marrow Transplantation, vol. 37, no. 1, pp. 1–18, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Martinez-Lopez, J. Blade, M.-V. Mateos et al., “Long-term prognostic significance of response in multiple myeloma after stem cell transplantation,” Blood, vol. 118, no. 3, pp. 529–534, 2011. View at Publisher · View at Google Scholar